



## NeuroMetrix, Inc. Announces Date for Second Quarter 2019 Financial Results Conference Call

July 11, 2019

WALTHAM, Mass., July 11, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2019 second quarter financial results before the opening of the market on Thursday, July 18, 2019. The Company will host a conference call at 8:00 a.m., Eastern Time on July 18, 2019 to discuss its financial results as well as business developments affecting the Company.

The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 7357689. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at [www.NeuroMetrix.com](http://www.NeuroMetrix.com) under the "Investor Relations" tab.

A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 800-585-8367, internationally. The confirmation code to access the replay is 7357689. The replay will be available for one week after the conference call.

### About NeuroMetrix

NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company markets Quell<sup>®</sup>, an over-the-counter wearable device for symptomatic relief of chronic pain. The company also markets DPNCheck<sup>®</sup>, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit [NeuroMetrix.com](http://NeuroMetrix.com).

NeuroMetrix, Inc.  
Thomas T. Higgins, 781-314-2761  
SVP and Chief Financial Officer  
[neurometrix.ir@neurometrix.com](mailto:neurometrix.ir@neurometrix.com)

Source: NeuroMetrix, Inc.



Source: NeuroMetrix, Inc.